Free tool
Cell therapy stocks
We cover 7 companies grouped under the Cell therapy theme. The median market value in the group is $43.63M. Across the group, the median move over the past trading day is −0.56%. Price change over the past year runs from −59.4% to −20.2% across the middle 80 percent of the group, with a median of −26.2%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $94.15M | Micro cap | −24.05% | Nov 12, 2026 |
| ACET | Adicet Bio, Inc. | $83.79M | Micro cap | −26.01% | Nov 11, 2026 |
| INKT | MiNK Therapeutics, Inc. | $60.16M | Micro cap | −26.22% | Nov 12, 2026 |
| TVGN | Tevogen Inc. | $43.63M | Micro cap | −85.43% | Nov 13, 2026 |
| PSH0.DE | Sernova Biotherapeutics Inc | $30.82M | Micro cap | −27.68% | Sep 10, 2026 |
| SVA.TO | Sernova Biotherapeutics Inc | $29.93M | Micro cap | −42.11% | Sep 10, 2026 |
| LGVN | Longeveron Inc. | $21.68M | Micro cap | −14.44% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.